Musa Sari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Musa Sari has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alper Zöngür
Gemerek Vocational School, Sivas Cumhuriyet University, Sivas, Turkey
2 shared publications - Bekir Dagdeviren
Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Firat University, Elazig, Türkiye
1 shared publication - Elif Emre
Firat Universitesi, Tip Fakultesi
1 shared publication - İsmail Polat
Department of Cardiology, Fethi Sekin City Hospital, Elazig 23300, Türkiye
1 shared publication - Mehdi Karasu
Department of Cardiology, Elazığ Fethi Sekin Şehir Hastanesi, Elazığ, Türkiye
1 shared publication - Ozlem Secen
Department of Cardiology, Fethi Sekin City Hospital, 23119 Elazig, Turkey
1 shared publication
Latest Publications
- 29 June 2026
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 47 (3) , 461-468
Determination of the Lethal Concentration (LC50) of Picloram and Linuron in Caenorhabditis Elegans
Herbicides account for approximately 52% of the global pesticide market share. In general, the use of herbicides has ensured weed control and significantly increased crop yields. Despite their positive effects on agriculture, first-generation herbicides have caused significant adverse effects on the environment and human health due to their high persistence and off-target toxicity. Growing awareness of human and environmental health has made it essential for newly developed herbicides to possess target specificity, high selectivity, low toxicity, and low application rates, as well as being economically and environmentally friendly. In many countries where tillage and irrigation methods for weed control have been reduced to conserve natural resources such as soil, water, and energy, herbicide use is on the rise. Most herbicides can be toxic to living organisms under conditions of high exposure. In this study, the toxic effects of certain doses of picloram and linuron on the lifespan of C. elegans were determined using LC50 (50% lethal concentration) values. In the study, the LC50 values were found as follows: LC50 6 hours = 5593 µM, LC50 12 hours = 5797 µM, LC50 18 hours = 1723 µM, LC50 24 hours = 699 µM. Similarly, the LC50 values for picloram were as follows: LC50 6 hours = 13263 µM, LC50 12 hours = 10247 µM, LC50 18 hours = 4157 µM, LC50 24 hours = 1921 µM. At the highest linuron dose (1000 µM), mortality rates of 26.6%, 31.6%, 46.6%, and 56.6% were observed at 6, 12, 18, and 24 hours, respectively. At the highest (1000 µM) picloram dose, mortality rates of 11.6%, 18.3%, 28.3%, and 40% were observed after 6, 12, 18, and 24 hours, respectively.
- 29 June 2026
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 47 (3) , 461-468
Determination of the Lethal Concentration (LC50) of Picloram and Linuron in Caenorhabditis Elegans
Herbicides account for approximately 52% of the global pesticide market share. In general, the use of herbicides has ensured weed control and significantly increased crop yields. Despite their positive effects on agriculture, first-generation herbicides have caused significant adverse effects on the environment and human health due to their high persistence and off-target toxicity. Growing awareness of human and environmental health has made it essential for newly developed herbicides to possess target specificity, high selectivity, low toxicity, and low application rates, as well as being economically and environmentally friendly. In many countries where tillage and irrigation methods for weed control have been reduced to conserve natural resources such as soil, water, and energy, herbicide use is on the rise. Most herbicides can be toxic to living organisms under conditions of high exposure. In this study, the toxic effects of certain doses of picloram and linuron on the lifespan of C. elegans were determined using LC50 (50% lethal concentration) values. In the study, the LC50 values were found as follows: LC50 6 hours = 5593 µM, LC50 12 hours = 5797 µM, LC50 18 hours = 1723 µM, LC50 24 hours = 699 µM. Similarly, the LC50 values for picloram were as follows: LC50 6 hours = 13263 µM, LC50 12 hours = 10247 µM, LC50 18 hours = 4157 µM, LC50 24 hours = 1921 µM. At the highest linuron dose (1000 µM), mortality rates of 26.6%, 31.6%, 46.6%, and 56.6% were observed at 6, 12, 18, and 24 hours, respectively. At the highest (1000 µM) picloram dose, mortality rates of 11.6%, 18.3%, 28.3%, and 40% were observed after 6, 12, 18, and 24 hours, respectively.
- Open Access
- 24 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5719
Enhanced Discrimination of Coronary Artery Disease Severity by Circulating Phoenixin-14: Evidence from a Clinical Laboratory Study
Early identification of anatomically significant coronary artery disease (CAD) remains a major clinical challenge despite advances in cardiovascular diagnostics. Novel circulating biomarkers may improve risk stratification and diagnostic discrimination beyond conventional parameters. We investigated the diagnostic utility of four emerging biomarkers—Phoenixin-14, Syntenin-1, Alamandine, and Cerebellin-1—for the assessment of CAD severity. In this prospective observational study, 90 participants undergoing coronary angiography were categorized into three groups: severe CAD (≥70% stenosis; n = 30), non-obstructive/non-critical CAD (n = 30), and angiographically normal controls (n = 30). Patients with acute coronary syndrome, diabetes mellitus, prior coronary revascularization, cardiomyopathy, or significant systemic disease were excluded. Circulating biomarker concentrations were quantified using the enzyme-linked immunosorbent assay. Comparative analyses, correlation testing, and receiver operating characteristic (ROC) analyses were performed to evaluate discriminatory performance. Circulating Phoenixin-14 concentrations progressively declined across the control, non-critical CAD, and severe CAD groups [40.1 (29.0–49.7) vs. 24.4 (18.5–30.1) vs. 16.7 (13.4–19.0) pg/mL, respectively; p < 0.001]. Phoenixin-14 demonstrated outstanding discrimination for severe CAD, achieving an area under the ROC curve (AUC) of 0.969 (95% CI, 0.888–0.997), with 86.7% sensitivity and 96.7% specificity at a threshold of ≤20.2 pg/mL. Diagnostic performance was substantially lower for Syntenin-1 (AUC, 0.795), Alamandine (AUC, 0.661), and Cerebellin-1 (AUC, 0.597). Phoenixin-14 also showed robust discrimination for non-critical CAD (AUC, 0.832). Biomarker concentrations exhibited correlations with metabolic indices while remaining largely independent of traditional cardiovascular risk factors. Among the evaluated novel circulating biomarkers, Phoenixin-14 demonstrated superior diagnostic performance for both obstructive and non-obstructive CAD, markedly outperforming Syntenin-1, Alamandine, and Cerebellin-1. These findings identify Phoenixin-14 as a promising candidate biomarker for CAD severity assessment and clinical risk stratification. Larger multicenter studies are warranted to validate these exploratory findings and determine their incremental value in contemporary cardiovascular practice.
- 24 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5719
Open AccessEnhanced Discrimination of Coronary Artery Disease Severity by Circulating Phoenixin-14: Evidence from a Clinical Laboratory Study
Early identification of anatomically significant coronary artery disease (CAD) remains a major clinical challenge despite advances in cardiovascular diagnostics. Novel circulating biomarkers may improve risk stratification and diagnostic discrimination beyond conventional parameters. We investigated the diagnostic utility of four emerging biomarkers—Phoenixin-14, Syntenin-1, Alamandine, and Cerebellin-1—for the assessment of CAD severity. In this prospective observational study, 90 participants undergoing coronary angiography were categorized into three groups: severe CAD (≥70% stenosis; n = 30), non-obstructive/non-critical CAD (n = 30), and angiographically normal controls (n = 30). Patients with acute coronary syndrome, diabetes mellitus, prior coronary revascularization, cardiomyopathy, or significant systemic disease were excluded. Circulating biomarker concentrations were quantified using the enzyme-linked immunosorbent assay. Comparative analyses, correlation testing, and receiver operating characteristic (ROC) analyses were performed to evaluate discriminatory performance. Circulating Phoenixin-14 concentrations progressively declined across the control, non-critical CAD, and severe CAD groups [40.1 (29.0–49.7) vs. 24.4 (18.5–30.1) vs. 16.7 (13.4–19.0) pg/mL, respectively; p < 0.001]. Phoenixin-14 demonstrated outstanding discrimination for severe CAD, achieving an area under the ROC curve (AUC) of 0.969 (95% CI, 0.888–0.997), with 86.7% sensitivity and 96.7% specificity at a threshold of ≤20.2 pg/mL. Diagnostic performance was substantially lower for Syntenin-1 (AUC, 0.795), Alamandine (AUC, 0.661), and Cerebellin-1 (AUC, 0.597). Phoenixin-14 also showed robust discrimination for non-critical CAD (AUC, 0.832). Biomarker concentrations exhibited correlations with metabolic indices while remaining largely independent of traditional cardiovascular risk factors. Among the evaluated novel circulating biomarkers, Phoenixin-14 demonstrated superior diagnostic performance for both obstructive and non-obstructive CAD, markedly outperforming Syntenin-1, Alamandine, and Cerebellin-1. These findings identify Phoenixin-14 as a promising candidate biomarker for CAD severity assessment and clinical risk stratification. Larger multicenter studies are warranted to validate these exploratory findings and determine their incremental value in contemporary cardiovascular practice.
- Open Access
- 26 March 2023
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 44 (1) , 7-12
Toxicity of Paraquat and Dicamba on Caenorhabditis Elegans LC50 Value
Paraquat and dicamba are chemicals commonly used in agriculture for plant control. The US Environmental Protection Agency (EPA) has classified paraquat into a restricted use class for use only by practitioners, as it is highly toxic. In this study, the effects of different concentrations of paraquat and dicamba toxic substances on C. elegans were studied. In tests, C. elegans were directly exposed to different concentrations of paraquat and dicamba for 6h, 12h, 18h, 24h. In particular, it was determined at which paraquat and dicamba doses that half of the C. elegans individuals (LC50) died. In the analysis results, paraquat LC50 values were found as LC50 6h= LC50 6h= 7412 µM, LC50 12h= 459 µM, LC50 18h= 123 µM, LC50 24h= 61 µM. Similarly, dicamba LC50 values were found as LC50 6h= 14610 µM, LC50 12h= 1404 µM, LC50 18h= 906 µM, LC50 24h= 463 µM.
- 26 March 2023
- Published by Cumhuriyet University in Cumhuriyet Science Journal
- Vol. 44 (1) , 7-12
Open AccessToxicity of Paraquat and Dicamba on Caenorhabditis Elegans LC50 Value
Paraquat and dicamba are chemicals commonly used in agriculture for plant control. The US Environmental Protection Agency (EPA) has classified paraquat into a restricted use class for use only by practitioners, as it is highly toxic. In this study, the effects of different concentrations of paraquat and dicamba toxic substances on C. elegans were studied. In tests, C. elegans were directly exposed to different concentrations of paraquat and dicamba for 6h, 12h, 18h, 24h. In particular, it was determined at which paraquat and dicamba doses that half of the C. elegans individuals (LC50) died. In the analysis results, paraquat LC50 values were found as LC50 6h= LC50 6h= 7412 µM, LC50 12h= 459 µM, LC50 18h= 123 µM, LC50 24h= 61 µM. Similarly, dicamba LC50 values were found as LC50 6h= 14610 µM, LC50 12h= 1404 µM, LC50 18h= 906 µM, LC50 24h= 463 µM.